Boston Scientific Corporation $BSX Shares Purchased by Comerica Bank

Comerica Bank increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 4.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 288,756 shares of the medical equipment provider’s stock after acquiring an additional 12,067 shares during the period. Comerica Bank’s holdings in Boston Scientific were worth $29,130,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of BSX. Colonial Trust Co SC grew its holdings in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 260 shares during the period. Investment Management Corp VA ADV acquired a new position in Boston Scientific during the fourth quarter worth about $25,000. Sunbeam Capital Management LLC acquired a new position in Boston Scientific during the fourth quarter worth about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the 1st quarter valued at $27,000. Finally, Ameriflex Group Inc. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $31,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Up 0.7%

BSX opened at $105.9950 on Monday. Boston Scientific Corporation has a fifty-two week low of $78.53 and a fifty-two week high of $108.94. The business has a 50-day moving average of $104.10 and a 200-day moving average of $102.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $157.06 billion, a PE ratio of 63.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.66.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the business earned $0.62 EPS. The business’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the transaction, the chief executive officer directly owned 1,476,882 shares in the company, valued at $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 345,029 shares of company stock worth $35,976,603. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BSX shares. Barclays increased their price target on Boston Scientific from $125.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Truist Financial increased their price target on Boston Scientific from $120.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Oppenheimer increased their price target on Boston Scientific from $110.00 to $118.00 and gave the company a “market perform” rating in a research report on Thursday, July 24th. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, April 29th. Finally, UBS Group increased their price target on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Buy” and a consensus price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.